EVERY secures US$55 million to scale precision-fermented egg proteins across the USA

The EVERY Company has raised US$55 million in Series D funding to accelerate nationwide commercialization of its precision-fermented egg proteins, positioning the California-based startup for large-scale distribution and profitability amid growing demand for reliable, animal-free ingredients.

The round was led by McWin Capital Partners through its McWin Food Tech Fund, with participation from Main Sequence, Bloom8, TO.VC, Minerva Foods, Grosvenor Food & Ag, New Agrarian, SOSV, and others. Proceeds will be used to expand manufacturing capacity, strengthen operations, and drive adoption across the US$270 billion global egg market, particularly in high-volume bakery applications.

“This new injection of capital will allow us to make good on our promise of making products that are accessible to everyone – in every state, every city, and every grocery store,” said Arturo Elizondo, Co-founder and CEO of EVERY. “This milestone fundraise is a powerful validation of our ambitions and we’re grateful for the trust of our incredible investors.”

The funding follows a year of rapid commercial progress for EVERY, which produces functional egg proteins using precision fermentation. Its ingredients, including OvoPro and OvoBoost, are already used in multiple consumer products, with new launches set to appear this month in Walmart stores nationwide.

“EVERY has crossed the line from promise to proof,” said Martin Davalos, Partner and Head of Food Tech at McWin Capital Partners. “They’re not talking about pilots – they’re selling metric tons of product at scale to some of the biggest food companies on the planet. EVERY is exactly the type of platform that will define the next decade of food production.”

The company’s expansion comes as the egg industry continues to face volatile pricing and supply instability due to avian flu outbreaks, rising feed costs, and other market pressures. By producing egg proteins through fermentation instead of farming, EVERY offers food manufacturers a consistent, pathogen-free, and cage-free-compliant alternative that performs like conventional eggs in functionality and flavor.

“If the last two years have taught us anything, it’s that our current food system remains incredibly fragile,” Elizondo said. “One outbreak can wipe out hundreds of millions of hens. For food companies small and large, that kind of risk just isn’t tenable – and we now have the answer.”

EVERY’s production model is designed for stability and scale. Its proteins are made year-round in fermentation tanks rather than on farms, eliminating exposure to disease, seasonality, and supply shocks. The resulting ingredients are shelf-stable powders with an 18-month shelf life, simplifying logistics and removing the need for cold storage – a major advantage for bakeries and other manufacturers that depend on liquid eggs.

“EVERY is proving what this technology can do – real products solving real customer problems, at industrial scale, with a clear path to profitability,” said Phil Morle, Partner at Main Sequence. “Their progress shows how biomanufacturing has matured into a resilient, scalable part of the global food supply chain. This is a massive opportunity to build the next generation of food production.”

The company manufactures several precision-fermented proteins that are functionally identical to those found in chicken eggs. Its flagship ingredient, OvoPro (ovalbumin, formerly known as EVERY EggWhite), provides the binding, foaming, and texturizing properties of egg whites in baked goods, confections, and sauces. Its companion ingredient, OvoBoost (formerly EVERY Protein), is a highly soluble, neutral-tasting protein that can be used to fortify beverages, syrups, and other foods without altering flavor or texture.

EVERY’s focus on ingredient functionality has helped it attract partnerships with global food and beverage manufacturers seeking to secure more stable protein supply chains. The company says it is now consistently producing metric tons of protein per month and is expanding capacity to meet growing demand.

“With this investment and the backing of forward-thinking partners, we’re one step closer to building a more secure, sustainable, and accessible global food system,” Elizondo said.